Anlv Biotechnology
Finnrick has tested 19 samples from Anlv Biotechnology across 5 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| GHK-Cu | 4 | 15 Jan 2026 | 22 Feb 2026 | |||||
| Survodutide | 3 | 17 Nov 2025 | 19 Jan 2026 | |||||
| Tirzepatide | 7 | 31 Aug 2025 | 7 Mar 2026 | |||||
| Tesamorelin | 4 | 31 Aug 2025 | 7 Mar 2026 | |||||
| Cagrilintide | 1 | 7 Mar 2026 | 7 Mar 2026 | |||||
The Anlv Biotechnology samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Most recent Anlv Biotechnology tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 7 Mar 2026 | Tesamorelin | View | 10mg | 12.5mg | +25.0% | 99.80% | TSM10HN202602 | No Label / Silver Crimp / Clear Blue Cap | Lab G | Public | |
| 7 Mar 2026 | Tirzepatide | View | 10mg | 10.8mg | +8.0% | 99.80% | TR10HN202602 | No Label / Silver Crimp / Yellow Cap | Lab G | Public | |
| 7 Mar 2026 | Cagrilintide | View | 10mg | 11.7mg | +17.0% | 99.90% | CGL10HN202602 | No Label / Silver Crimp / Green Cap | Lab G | Public | |
| 22 Feb 2026 | GHK-Cu | View | 50mg | 52.4mg | +4.8% | 99.79% | (no batch ID) | White Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 20 Feb 2026 | Tesamorelin | View | 10mg | 11.6mg | +16.0% | 99.88% | (no batch ID) | White Label / Silver Crimp / White Cap | Lab E | Public | |
| 20 Feb 2026 | Tirzepatide | View | 20mg | 25.7mg | +28.5% | 99.90% | (no batch ID) | No Label / Silver Crimp / Violet Cap | Lab E | Public | |
| 20 Feb 2026 | Tirzepatide | View | 10mg | 10.3mg | +3.0% | 99.90% | (no batch ID) | No Label / Silver Crimp / Yellow Cap | Lab E | Public | |
About Anlv Biotechnology Test Results From Finnrick
Anlv Biotechnology is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 5 products and 19 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud). Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Anlv Biotechnology Testing Activity & Score Summary
In the past 30 days, Finnrick has published no new test results for Anlv Biotechnology. The overall dataset includes 19 tested samples with an average score of 7.4/10 across all products.
Across 19 identity-tested samples, 100% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.9%. Approximately 95% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Tirzepatide (7 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 4.9 to 10.0 (average 7.4/10), suggesting significant batch-to-batch differences.
- GHK-Cu (4 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 6.9 to 9.5 (average 8.0/10), suggesting significant batch-to-batch differences.
- Tesamorelin (4 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 1.4 to 10.0 (average 5.9/10), suggesting significant batch-to-batch differences.